FDA
-
-
-
-
-
-
-
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
-
-
-
-
-
-
-
Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Exelixis (EXEL)
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

